47 results
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Aug 23
Notice of Annual General and Special Meeting of Shareholders
5:15pm
Law"). Each member of the Audit Committee shall be "financially literate" and at least one member of the Audit Committee shall be a "financial expert
20-F/A
2021 FY
REPCF
Replicel Life Sciences Inc.
12 Sep 22
Annual report (foreign) (amended)
6:17pm
.
ITEM 16A Audit Committee Financial Expert
Our board of directors has determined that at least one member of its audit committee, being Mr. Peter … Lewis, qualifies as an "audit committee financial expert" as defined in Item 16A(b) of Form 20-F. Mr. Lewis is also "independent" as that term
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
18 Nov 21
Notice of Annual General and Special Meeting of Shareholders
10:36am
of the Audit Committee shall be a "financial expert", as such terms are defined by the Applicable Law.
Members of the Audit Committee shall be appointed
6-K
EX-99.1
93f9p68qsl
18 Aug 21
Current report (foreign)
12:20pm
20-F/A
807pdf
31 Mar 21
Annual report (foreign) (amended)
12:00am
6-K
EX-99.5
yp8xsaalbibej
3 Feb 21
RepliCel and MainPointe Pharmaceuticals Sign Strategic Investment and Collaboration Agreement
12:03pm
6-K
EX-99.3
smpn1aniasa kjw0js1
3 Feb 21
RepliCel and MainPointe Pharmaceuticals Sign Strategic Investment and Collaboration Agreement
12:03pm
6-K
EX-99.1
fpd4u82cy5fg fue4ahh
13 Nov 20
Notice of Annual General and Special Meeting of Shareholders
12:00am
6-K
EX-99.1
dc5qkq 8v
6 Nov 19
Notice of Annual General and Special Meeting of Shareholders
12:00am
6-K
EX-99.1
wxhbp dbm
22 Jan 19
Current report (foreign)
4:43pm
6-K
EX-99.1
irvh4csfpom
6 Nov 18
RepliCel Life Sciences Appoints Head of Clinical and Regulatory Affairs
11:03am
20-F/A
nd6rfmyp 2in
12 Jan 18
Annual report (foreign) (amended)
12:00am